CSL (ASX:CSL) share price pops on increased dividend

The CSL (ASX: CSL) share price is higher today after the biotech announced a dramatic lift in profits and boosted dividend for the half-year.

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are trending higher in early trade today following the release of the pharmaceutical giant's half-year results. At the time of writing the CSL share price is 2.38% higher at $287.89.

Profits in tip-top shape

All eyes were on the CSL share price this morning following the release of the company's results. Fortunately, the numbers did not disappoint, sending CSL shares higher in morning trade.

The most exhilarating number to come out of the half-year report was the company's bumper profit. Due to increased margins, CSL managed to deliver a 45% increase to its reported net profit after tax of US$1,810 million.

Additionally, CSL's revenue grew to US$5,739 million. Although not as substantial an increase in percentage terms, at 16.9%, the top-line growth is significant. The driving force behind the increase was a 9% lift in CSL Behring revenue and a 38% jump in Seqirus revenue.

Importantly, it appears the business segment responsible for the seasonal flu vaccine has contributed largely to the result. Seqirus added US$693 million to earnings before interest and tax – an increase of 112%.

Increased CSL dividend

As a result of the strong numbers, the CSL board increased the interim dividend by 9% to US$1.04 per share. Unfortunately, the weak US dollar to AUD means this payout is 9% lower than the prior corresponding period on a constant currency basis.

By chief executive officer and managing director Paul Perreault's account, the future for CSL remains rosy: "Demand for CSL's core plasma, and influenza vaccine products remain robust."

However, there is expected to be a lift in costs in the next half as the biotech builds its research up again, after falling due to COVID-19 vaccine development efforts.

CSL share price under the microscope

The CSL share price has taken a beating over the last year, down by around 13%. COVID-19 disruptions and vaccine development efforts weighed on the business and its usual operations.

However, in the last month, the share price has experienced a reasonable 7.6% lift as some geographies return to normal.

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Piggy bank sinking in water symbolising a record low share price.
52-Week Lows

9 ASX 200 shares tumbling to 52-week lows today

Israel's strike on Iran on Friday dragged several ASX 200 shares to new depths.

Read more »

Female miner smiling at a mine site.
Share Gainers

Up 834% in a year, guess which ASX mining stock is hitting new all-time highs today

The ASX mining stock has gone from strength to strength over the past year.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why COG, Karoon Energy, Netwealth, and Pilbara Minerals shares are dropping today

These ASX shares are ending the week deep in the red. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Fiducian Group, Northern Star, Paradigm, and Santos shares are charging higher

These shares are avoiding the market selloff.

Read more »

Dollar sign in yellow with a red falling arrow in front of a graph, symbolising a falling share price.
Share Market News

Why did the ASX 200 just sink to new 2-month lows on Friday?

It’s been a rocky week for the ASX 200. But why?

Read more »

Woman looking at a phone with stock market bars in the background.
Opinions

I'm buying these quality ASX shares to capitalise on the decline

These are the shares I'd buy if the markets get any worse.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Broker Notes

Why this ASX 100 stock can rise 14% to a new 52-week high

Goldman Sachs thinks investors should be buying this top stock now.

Read more »